iCAD, Inc. (ICAD) Showcases AI-Powered Breast Health Innovations at ECR 2025

iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered breast health solutions, is set to showcase its latest advancements at the European Congress of Radiology (ECR) 2025, taking place from February 26 to March 2, 2025, in Vienna, Austria. The company's presentations and live demonstrations at booth AI-27, Hall X-1, will highlight its commitment to pushing the boundaries of AI innovation in breast health and empowering radiologists with cutting-edge solutions to improve clinical outcomes, enhance workflow efficiency, and support personalized patient care.

iCAD's participation at ECR 2025 will feature five clinical presentations and abstracts, led by research collaborators, that underscore the company's dedication to delivering artificial intelligence (AI) powered solutions to advance personalized risk assessment, enhance early detection, and optimize breast imaging workflows. These studies will be presented in oral and virtual poster formats, covering a range of topics, including the role of AI in breast imaging, optimal utilization of AI diagnostic software in mammography screening programs, personalized risk prediction of breast cancer, and the development of a breast arterial calcification detection algorithm.

One of the key highlights of iCAD's presence at ECR 2025 will be the unveiling of the new ProFound Cloud, a secure, scalable SaaS platform designed to deliver the company's advanced AI solutions to healthcare providers worldwide. The ProFound Cloud provides fast, flexible, and scalable access to iCAD's ProFound full suite of solutions, including DBT Detection, 2D Detection, Density Assessment, and Risk. This new platform reinforces iCAD's leadership in AI-driven breast health solutions and its commitment to empowering radiologists with the most advanced tools to improve patient outcomes.

iCAD's participation at ECR 2025 comes on the heels of the company's recent announcement of the FDA clearance of ProFound Detection Version 4.0, an advanced AI solution that enhances breast cancer detection by incorporating prior exams into current analysis. This next-generation AI solution improves sensitivity by 22% and reduces cases with no marks by 18%, providing clinicians with more reliable insights for better decision-making. The clearance of ProFound Detection Version 4.0 further solidifies iCAD's position as a leader in AI-powered breast health solutions and its commitment to advancing personalized risk evaluation, improving early detection, and optimizing breast imaging workflows.

In addition to its clinical presentations and the launch of the ProFound Cloud, iCAD will showcase its latest AI-powered breast health innovations at its booth, AI-27, Hall X-1. These live demonstrations will provide attendees with the opportunity to experience firsthand the company's advanced AI solutions and their real-world impact on breast cancer detection, risk evaluation, and breast arterial calcification assessment.

iCAD's presence at ECR 2025 underscores the company's commitment to pushing the boundaries of AI innovation in breast health and empowering radiologists with cutting-edge solutions to improve clinical outcomes, enhance workflow efficiency, and support personalized patient care. By showcasing its latest advancements and collaborating with research partners, iCAD continues to lead the way in AI-driven breast health solutions, ultimately supporting better outcomes for patients and providers worldwide.